In English | En español
Questions About Cancer? 1-800-4-CANCER

Pancreatic Cancer Treatment (PDQ®)

  • Last Modified: 02/21/2014

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document

Changes to This Summary (02/21/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Pancreatic Cancer

Updated statistics with estimated new cases and deaths for 2014 (cited American Cancer Society as reference 1).

Stage I and Stage II Pancreatic Cancer Treatment

Revised text to state that median disease-free survival was 13.4 months in the gemcitabine arm and 6.7 months in the observation arm. Also added that in the initial publication of results, there was no significant difference in overall survival (OS) between the gemcitabine arm and the control arm.

Added text to state that with a median follow-up of 136 months, long-term follow-up of the CONKO-001 study demonstrates a significant improvement in OS that favors gemcitabine. Also added that gemcitabine compared with observation alone yielded improved survival rates at 5 years of 20.7% for the gemcitabine arm versus 10.4% for the observation-alone arm and survival rates at 10 years were 12.2% for the gemcitabine arm versus 7.7% for the observation-alone arm (cited Oettle et al. as reference 21 and level of evidence 1iiA).

Stage III Pancreatic Cancer Treatment

Revised text in the chemotherapy treatment option to add gemcitabine and nab-paclitaxel.

Added text to include a multicenter, international phase III trial of gemcitabine and nab-paclitaxel versus gemcitabine alone as evidence that nab-paclitaxel plus gemcitabine is a standard treatment option for patients with advanced pancreatic cancer. Also added that the trial included 861 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy for metastatic disease (cited Von Hoff et al. as reference18 and level of evidence 1iiA). Added that the median OS and the median progression-free survival (PFS) favored the nab-paclitaxel/gemcitabine group; however, nab-paclitaxel/gemcitabine was more toxic than gemcitabine. Quality-of-life data have not yet been published.

Stage IV Pancreatic Cancer Treatment

Added text to include a multicenter, international phase III trial of gemcitabine and nab-paclitaxel versus gemcitabine alone as evidence that nab-paclitaxel plus gemcitabine is a standard treatment option for patients with advanced pancreatic cancer. Also added that the trial included 861 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy for metastatic disease (cited Von Hoff et al. as reference 20 and level of evidence 1iiA). Added that the median OS and the median PFS favored the nab-paclitaxel/gemcitabine group; however, nab-paclitaxel/gemcitabine was more toxic than gemcitabine. Quality-of-life data have not yet been published.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.